PLoS ONE (Jan 2024)

Mexenone protects mice from LPS-induced sepsis by EC barrier stabilization.

  • Yoon Ji Choi,
  • Jimin An,
  • Ji Hye Kim,
  • Sa Bin Lee,
  • Bo Seok Lee,
  • Chae Young Eom,
  • Hyohi Lee,
  • Nayeong Kwon,
  • Il Shin Kim,
  • Kyoung-Su Park,
  • Sooah Park,
  • Jung-Woog Shin,
  • Sanguk Yun

DOI
https://doi.org/10.1371/journal.pone.0302628
Journal volume & issue
Vol. 19, no. 5
p. e0302628

Abstract

Read online

Blood vessels permit the selective passage of molecules and immune cells between tissues and circulation. Uncontrolled inflammatory responses from an infection can increase vascular permeability and edema, which can occasionally lead to fatal organ failure. We identified mexenone as a vascular permeability blocker by testing 2,910 compounds in the Clinically Applied Compound Library using the lipopolysaccharide (LPS)-induced vascular permeability assay. Mexenone suppressed the LPS-induced downregulation of junctional proteins and phosphorylation of VE-cadherin in Bovine Aortic Endothelial Cells (BAECs). The injection of mexenone 1 hr before LPS administration completely blocked LPS-induced lung vascular permeability and acute lung injury in mice after 18hr. Our results suggest that mexenone-induced endothelial cell (EC) barrier stabilization could be effective in treating sepsis patients.